Semnur Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Semnur Pharmaceuticals, Inc. (SMNR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $19.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-10
- Semnur Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $83.00K.
- Semnur Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$5.00K.
- Semnur Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$203.45K.
- Semnur Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$240.40K.
- Semnur Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$615.28K, a 175.06% decline from fiscal 2022.
- Semnur Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $819.75K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.00K 10-Q · filed 2026-08-10 | |||||||
| 2026-03-31 | $83.00K 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | $8.00K S-1 · filed 2026-05-12 | |||||||
| 2025-09-30 | $73.00K 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | $43.00K 10-Q · filed 2026-08-10 | -$16.74K 10-Q · filed 2025-08-15 | ||||||
| 2025-03-31 | -$5.00K 10-Q · filed 2026-05-13 | -$14.13K 10-Q · filed 2025-05-16 | ||||||
| 2024-12-31 | $0.00 S-1 · filed 2026-05-12 | -$187.60K 10-K · filed 2025-04-02 | ||||||
| 2024-09-30 | $1.00K 10-Q · filed 2025-11-12 | -$190.18K 10-Q · filed 2024-11-19 | ||||||
| 2024-06-30 | -$202.96K 10-Q · filed 2025-08-15 | |||||||
| 2024-03-31 | -$203.45K 10-Q · filed 2025-05-16 | |||||||
| 2023-12-31 | -$615.28K 10-K · filed 2025-04-02 | |||||||
| 2023-09-30 | -$806.29K 10-Q · filed 2024-11-19 | |||||||
| 2023-06-30 | -$810.62K 10-Q · filed 2024-08-19 | |||||||
| 2023-03-31 | -$240.40K 10-Q · filed 2024-05-22 | |||||||
| 2022-12-31 | $819.75K 10-K · filed 2024-04-01 | |||||||
| 2022-09-30 | $985.58K 10-Q · filed 2023-11-09 |